By Katrina Thornber
Publication Date: 2025-11-29 15:00:00
A NEW tool could transform early diagnosis as an artificial intelligence program has significantly improved the detection of transthyretin cardiac amyloidosis in a major health system. The study found that targeted AI screening resulted in significantly more confirmed cases and timely treatment.
Expanding efforts to detect transthyretin cardiac amyloidosis earlier
Efforts to improve detection of transthyretin cardiac amyloidosis have intensified as treatment options expanded and awareness of the disease increased. Nevertheless, ATTR-CM remains underdiagnosed and often presents with subtle cardiac and orthopedic symptoms that delay referral to a specialist. Detecting cases earlier could change outcomes, and AI-powered programs are currently being studied as a possible way to reduce missed or delayed diagnoses. The need for improved detection is particularly important as the prevalence of transthyretin cardiac amyloidosis increases as the population ages.
